BioNTech Singapore Plant Closure 2027: What the mRNA Manufacturing Correction Means for Asia Pacific Biopharma

BIONTECH CLOSES SINGAPORE VACCINE MANUFACTURING PLANT BY FEBRUARY 2027

BioNTech Shuts Singapore Manufacturing Site by 2027: What It Means for the mRNA and Clinical Trials Landscape

On April 1, 2026, German biotechnology firm BioNTech confirmed it will close its vaccine and therapeutic drug manufacturing facility in Singapore by the end of February 2027. The announcement marks a decisive strategic retreat from pandemic-era infrastructure investment and signals a broader reconfiguration of BioNTech's global manufacturing footprint as the company pivots toward its oncology and next-generation mRNA therapeutics pipeline.

The Singapore plant, located in the Tuas Biomedical Park, was acquired from Swiss pharmaceutical company Novartis in November 2022 at the height of BioNTech's financial peak. Following the extraordinary commercial success of Comirnaty, its Pfizer-partnered COVID-19 vaccine, BioNTech committed to building a regional headquarters and manufacturing hub in Singapore capable of producing several hundred million mRNA vaccine doses annually. The facility was also intended to support the development and manufacture of cancer vaccines and other therapeutics for both clinical and commercial use. The facility currently employs 85 people, all of whom will receive severance packages and outplacement support.

The decision to close comes against a backdrop of significant financial deterioration. BioNTech reported a net loss of approximately 1.14 billion euros in 2025, following a 665 million euro loss in 2024. The company recorded modest revenue growth of around 4 percent in 2025 but forecasts a revenue decline of approximately 25 percent in 2026, driven primarily by collapsing demand for COVID-19 vaccines in the United States and European markets. With cancer vaccines from BioNTech and most of its peers still in development rather than commercial production, the Singapore site could not be justified at its current scale.

The closure does not stand alone. US pharmaceutical giant Merck (known as MSD outside the US) announced in March 2026 that it would also close one of its Tuas manufacturing facilities in Singapore, though it declined to specify production volumes or exact employee numbers. Both closures reflect a sector-wide correction after years of rapid capacity expansion driven by pandemic demand that has since normalized. MSD has been operating in Singapore since 1997 and invested more than 2 billion US dollars in the country, yet still announced significant job and cost cuts in 2025 aimed at saving 3 billion US dollars globally.

For Singapore's biomedical sciences sector, the closures are a material development. The sector accounts for approximately 1.9 percent of Singapore's GDP and generates output exceeding 32 billion Singapore dollars annually while employing more than 26,000 people. The country's Economic Development Board is working closely with both BioNTech and MSD, alongside Workforce Singapore and NTUC's Employment and Employability Institute, to support affected employees through job placements and retraining.

BioNTech has framed the decision as a realignment of capacity with its long-term clinical portfolio rather than an exit from Asia. The company is also navigating a major leadership transition: co-founders and CEO Ugur Sahin and CMO Ozlem Tureci are both scheduled to depart by the end of 2026 to found a new venture. This coincides with a planned board recommendation at the upcoming AGM to carry forward the company's approximately 6.9 billion euros in retained earnings to fund its oncology pipeline, signaling where BioNTech sees its future value creation.

For the clinical trials community, the closure raises practical questions about mRNA manufacturing capacity in the Asia-Pacific region at a time when long-acting injectables and next-generation mRNA-based cancer vaccines are advancing through clinical development. BioNTech's shift from pandemic infrastructure to oncology-focused clinical manufacturing mirrors a broader industry pattern. Moderna, which faced similar commercial pressures, has also adjusted its manufacturing strategy significantly since 2022.

The BioNTech plant closure is a sobering marker of how quickly the post-pandemic pharmaceutical economy has recalibrated. The Singapore investment was rational in 2022; the mRNA platform had demonstrated unprecedented speed and scale, and BioNTech had logged 17.3 billion euros in annual revenue that year alone. By 2025, that same platform was generating losses. What changes between those two moments is not the quality of the science but the structure of the market. The clinical trials world will be watching how BioNTech reallocates its manufacturing capabilities as its cancer vaccine candidates, including personalized mRNA tumor vaccines in partnership with Pfizer, approach potential commercialization in the coming years.

Sources: The Straits Times (April 1, 2026) | Fierce Pharma | BioProcess Insider | BioPharm International | BioNTech Financial Disclosures 2025